Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Poitiers University Hospital30 enrolled

Overview

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obstructive Sleep Apnea-hypopnea Oropharyngeal Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age\> 18 years old * Performance Status 0-2 * Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy * Treatment termination time greater than 6 months at inclusion * Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3 * Patient in complete remission at inclusion * patient's consent's obtained after information Exclusion Criteria: * Previous treatment for upper aerodigestive tract cancer * Incomplete radiotherapyTreatment * Neurological pathology wich may affect the functions of the upper aerodigestive tract * Pregnant or breastfeeding woman * Unweaned alcoholism * Tracheotomized patient at the time of the study * Patient under protection: subjects with guardianship or under law protection * No health insurance coverage

Locations (1)

Outcomes

Primary Outcomes

Prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy.

Number of patients with obstructive sleep apnea hypopnea syndrome after treatment combined chemoradiotherapy.

Time frame: Day 28

Secondary Outcomes

Severity of OSAHS as a function of the post-therapeutic delay.

Value of the AHI as a function of the post-therapeutic delay which corresponds to the delay compared to the end of the curative treatment carried out for squamous cell carcinoma of the oropharynx. It is obtained after the inclusion visit and the realization of the polygraphy with the IAH score. OSAHS is mild (if IAH ≥ 5 / h and \<15 / h), moderate (if IAH ≥ 15 / h and ≤ 30 / h) or severe (if IAH\> 30 / h)